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Epigenetic switch drives the conversion of
ﬁbroblasts into proinvasive cancer-associated
ﬁbroblasts
Jean Albrengues1, Thomas Bertero1, Eloise Grasset1, Stephanie Bonan1, Majdi Maiel1, Isabelle Bourget1,
Claude Philippe1, Cecilia Herraiz Serrano2, Samia Benamar3, Olivier Croce1, Victoria Sanz-Moreno2,
Guerrino Meneguzzi1, Chloe C. Feral1, Gael Cristofari1 & Cedric Gaggioli1
Carcinoma-associated ﬁbroblasts (CAF) mediate the onset of a proinvasive tumour
microenvironment. The proinﬂammatory cytokine LIF reprograms ﬁbroblasts into a
proinvasive phenotype, which promotes extracellular matrix remodelling and collective
invasion of cancer cells. Here we unveil that exposure to LIF initiates an epigenetic switch
leading to the constitutive activation of JAK1/STAT3 signalling, which results in sustained
proinvasive activity of CAF. Mechanistically, p300-histone acetyltransferase acetylates
STAT3, which, in turn, upregulates and activates the DNMT3b DNA methyltransferase.
DNMT3b methylates CpG sites of the SHP-1 phosphatase promoter, which abrogates SHP-1
expression, and results in constitutive phosphorylation of JAK1. Sustained JAK1/STAT3
signalling is maintained by DNA methyltransferase DNMT1. Consistently, in human lung and
head and neck carcinomas, STAT3 acetylation and phosphorylation are inversely correlated
with SHP-1 expression. Combined inhibition of DNMTactivities and JAK signalling, in vitro and
in vivo, results in long-term reversion of CAF-associated proinvasive activity and restoration of
the wild-type ﬁbroblast phenotype.
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C
arcinoma-associated ﬁbroblasts (CAF) are key compo-
nents of solid tumour ecosystems, including breast, skin,
head and neck, prostate and lung cancers1–3. CAF play an
active role in tumour development and their presence within the
tumour stroma is associated with poor clinical outcome4–8.
Besides promoting primary tumours, CAF remodel the
tumour microenvironment by generation of tensile forces
within the extracellular matrix (ECM) that support favourable
cues for tumour invasion9–12. CAF-dependent excessive ECM
remodelling leads to tumour ﬁbrosis, which is associated with
tumour cell dissemination and metastasis13,14. CAF-dependent
proﬁbrotic activity is governed by constitutive activation
of the Janus kinase 1 (JAK1), which leads to constitutive
phosphorylation of its downstream target, the STAT3 (signal
transducer and activator of transcription 3) transcription factor15.
We have demonstrated that the proinﬂammatory LIF (leukaemia
inhibitory factor) cytokine initiates the sustained proinvasive
stromal ﬁbroblast phenotype observed in cancers16. However,
how the activated status of stromal ﬁbroblast is sustained remains
to be elucidated.
STAT3 belongs to a large family of transcription factors, and its
constitutive activation has been observed in 70% of solid and
haematological tumours17. STAT3-dependent transcriptional
activity is mediated by phosphorylation on tyrosines 705 and
727 by the JAK family kinases in response to cytokine-mediated
signalling18. Activated STAT3 translocates to the nucleus and
binds promoter DNA sequences to regulate targeted gene
transcription. STAT3 activity is enhanced by acetylation on
lysine 685 by the histone acetyltransferases (HAT) p300/CREB-
binding protein (CBP), a post-transcriptional modiﬁcation that is
reversed by histone deacetylases (HDACs)19–21. Acetylated
STAT3 binds to the DNA methyltransferase DNMT1, which
mediates targeted gene silencing by methylation of promoter
DNA sequences22. DNA methylation plays critical roles in
control of sustained and constitutive activation of signalling
pathways23. Overall, both tumour and stromal cell DNA are
hypomethylated; however, hypermetylation of CpG dinucleotides
in gene promoters is known to silence tumour-suppressor gene
expression24–28. Among the major DNA methyltransferases
(DNMTs), DNMT1 maintains pre-existing DNA methylation
patterns along with DNA replication and cell division; DNMT3a
and DNMT3b target unmethylated CpGs and introduce de novo
methylations29.
Here using combination of three-dimensional model of
organotypic invasion assays of head and neck and breast tumours,
and using in vitro and in vivo models of breast carcinomas,
we demonstrate that an epigenetic switch initiates and maintains
the proinvasive phenotype of CAF. We show that LIF induces
constitutive activation of the JAK1/STAT3 signalling pathway
by post-translational regulation of STAT3 acetylation by p300, in
ﬁbroblasts. Acetylated STAT3 leads to an epigenetic-dependent
loss of expression of the SHP-1 tyrosine phosphatase, which
is a negative regulator of the JAK/STAT pathway. Silencing
of SHP-1 by promoter methylation leads to sustained
constitutive phosphorylation of the JAK1 kinase and the STAT3
transcription factor that maintain the contractile and proinvasive
ﬁbroblasts abilities. Blockage of both JAK signalling and DNA
methyltransferase activities both in vitro and in vivo results in
long-term proinvasive phenotypic reversion of CAF. Finally,
we corroborate our in vitro and in vivo ﬁndings through
immunhistological analysis of STAT3 activity and SHP-1
expression in both head and neck and lung human carcinoma
biopsies. Therefore, we conclude that in human carcinomas
from different origins, LIF induces a sustained proinvasive
activation of CAF through an epigenetic-dependent loss of
SHP-1 phosphatase.
Results
Epigenetic mechanisms sustain the proinvasive CAF phenotype.
We ﬁrst assessed whether, similar to CAF isolated from head
and neck, lung and breast human carcinomas (HN-CAF,
Lu-CAF and Br-CAF, respectively), the long-term LIF or
TGFb-activated human dermal ﬁbroblasts (hDF_LIF or
hDF_TGFb) constitutively retain their proinvasive properties.
hDF were stimulated for 7 days in culture using LIF or TGFb
in the presence or absence of a LIF blocking antibody.
After 15- 30- and 60-day culture in low serum concentration
(Fig. 1a), the hDF proinvasive ability was assessed using a
three-dimensional SCC12 cell organotypic invasion assay30.
In these conditions LIF induced the sustained ﬁbroblast
proinvasive phenotype (Fig. 1b) and, constitutively, the
JAK1/STAT3 signalling pathway (Supplementary Fig. 1a)
as observed with CAF compared with primary hDF
(Supplementary Fig. 1b). Interestingly, TGFb, the major
in vitro and in vivo CAF activator, relied on LIF to
constitutively activate the proinvasive ability of hDF (Fig. 1b)
and the JAK1/STAT3 signalling pathway (Supplementary
Fig. 1a). These results indicate that a 7-day LIF stimulation is
sufﬁcient to confer a long-term proinvasive CAF-like phenotype
to hDF. CAF secrete procarcinogenic factors, including
interleukin-6 (IL6)-family cytokines2 that may sustain
constitutive activation of JAK1 kinase via an autocrine
regulatory loop. Therefore, we investigated whether media
conditioned (CM) by CAF, hDF_LIF and hDF_TGFb can
activate JAK1/STAT3 signalling in hDF. Stimulation of hDF by
long-term CAF, LIF- and TGFb-activated hDF CM failed to
promote JAK1/STAT3 phosphorylation (Fig. 1c) and collagen
gel contraction (Fig. 1d), while short-term TGFb-activated CM
(hDF-TGFb-6 h), in which LIF is detectable16, promoted both
STAT3 phosphorylation and gel contraction (Fig. 1c,d).
Accordingly, in hDF_LIF, abrogation of GP130 receptor or
addition of a speciﬁc LIF blocking antibody failed to alter STAT3
phosphorylation, which contrasts with the abrogation of JAK1
expression (Supplementary Fig. 1c,d). Taken together, these data
demonstrate that LIF confers permanent proinvasive conversion
to hDF that is independent of a LIF autocrine signalling
regulatory loops but dependent on JAK1 activity. We thus
hypothesized that epigenetic modiﬁcations might be involved in
the constitutive activation of CAF and hDF_LIF. To test this
idea, HN-CAF-dependent three-dimensional matrix gel
contraction assays were performed in the presence of 45
small-molecule inhibitors targeting the epigenetic and DNA-
modiﬁer cell machinery (Fig. 1e, Supplementary Fig. 1e and
Supplementary Table 1). For each tested molecule, the screen
was performed at optimized concentrations (Supplementary
Table 1); dimethylsulphoxide was used as a control. Among the
six classes of inhibitors, three HAT p300 inhibitors (Garcinol,
Anacardic acid and C646) and three DNA methyltransferase
inhibitors (50-Aza-20-deoxycytidine, Zebularine and Decitabine)
blocked the CAF contractile capacity (Fig. 1e). Accordingly, the
p300 activator CTPB (N-(4-chloro-3-triﬂuoromethyl-phenyl)-2-
ethoxy-benzamide) signiﬁcantly increased CAF contractility
(Fig. 1e). Inhibition of matrix remodelling by both p300 and
DNMT inhibitors was further conﬁrmed in hDF_LIF
(Supplementary Fig. 1e). In light of these results, the role of
p300 in CAF- and hDF-LIF-dependent SCC12 cell invasion was
further investigated. Using C646, a small-molecule inhibitor, the
crucial role of p300 in proinvasive activity was established
(Supplementary Fig. 1f,g). These results demonstrate that LIF
governs the long-term activation of proinvasive ﬁbroblasts,
which also involves DNMTs and p300 activities, and further
suggests that the sustained phenotypes observed in CAF rely on
epigenetic modiﬁcations.
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Figure 1 | Epigenetic-dependent proinvasive ﬁbroblasts phenotype. (a) Schematic representation of experimental conditions for long-term maintenance
of the proinvasive properties of LIF- and TGFb1-activated ﬁbroblasts. (b) Representative images of haematoxylin and eosin (H&E) coloration of
parafﬁn-embedded sections of SCC12 in response to control hDF (Veh.) or hDF previously activated for 7 days with LIF or TGFb1, in presence or absence of
LIF blocking antibody (aLIF) after 15, 30 and 60 days of culture in 0.5% SVF media. Scale bar, 100mm. I.I., invasion index (n¼ 3; mean±s.d.; ***Po0.001).
(c) Immunoblot of pJAK1, pSTAT3 and pSMAD2 in hDF cells stimulated by three CAF-CM, long-term LIF and TGFb1-activated hDF-CM and short-term
TGFb-activated hDF-CM. Immunoblot of JAK1, STAT3, SMAD2 and tubulin as control. (d) Percentage of gel contraction by hDF stimulated by three
CAF-CM, long-term LIF and TGFb1-activated hDF-CM and short-term TGFb-activated hDF-CM (n¼ 3 in triplicate, meanþ s.d., ***Po0.001).
(e) Quantiﬁcation of matrix remodelling by CAF in the presence of small molecules inhibitors for 6 days. (n¼ 3 in triplicates).
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P300 mediates STAT3 acetylation for ﬁbroblast activation.
Screening for small-molecule inhibitors of the epigenetic cell
machinery identiﬁed p300 as a crucial regulator of proinvasive
ﬁbroblasts matrix remodelling in vitro. Indeed, in hDF, RNA
interference (RNAi)-mediated silencing of p300 before LIF
initiation resulted in blockage of the sustained proinvasive
property displayed by hDF_LIF (Fig. 2a,b). Interestingly, silencing
of p300 in HN-CAF resulted in loss of their proinvasive potential
(Supplementary Fig. 2a,b), which conﬁrmed the results obtained
in the contractility screens (Fig. 1e, Supplementary Fig. 1c).
Furthermore, the p300 small-molecule activator CTBP was
sufﬁcient to promote hDF-dependent matrix remodelling
(Supplementary Fig. 2c) and the sustained proinvasive cell
capacity (Supplementary Fig. 2d). Taken together, these data
showed that p300 plays a central role in the proinvasive ﬁbroblast
activation. Besides acetylating histones, p300 also acetylates
STAT3, which is crucial for STAT3 transcriptional activity21.
We then showed that in hDF, LIF induced p300 binding to
activate STAT3 (Fig. 2c) and RNAi silencing of p300 or blockage
of p300 activity by the C646 small-molecule inhibitor
inhibited the LIF-dependent constitutive activation of JAK1
phosphorylation and both the STAT3 phosphorylation on residue
tyrosine 705 and the acetylation on residue lysine K685
(Fig. 2b,d). Furthermore, activation of p300 by CTPB was
sufﬁcient to constitutively activate the JAK1/STAT3 signalling
pathway in hDF cells (Fig. 2e). This observation further conﬁrms
that p300 is responsible for STAT3 acetylation on LIF-dependent
proinvasive ﬁbroblast activation and suggests that STAT3
acetylation is pivotal in this process. At this stage, the role of
STAT3 acetylation in sustained ﬁbroblast proinvasive activity was
then assessed. Using organotypic invasion assays, hDF stably
expressing either green ﬂuorescent protein (GFP; empty-GFP), or
the wild-type form of STAT3 (STAT3-GFP) or a non-acetylated
STAT3 mutant fused to GFP (STAT3-K685R-GFP), were
investigated for their LIF-dependent sustained proinvasive
capacity. HDF_LIF overexpressing either the control or the
WT-STAT3 vector were found to retain proinvasive properties,
that were abrogated in cells expressing a non-acetylated form
of STAT3 (Fig. 2f). Furthermore, molecular analysis of the
JAK1/STAT3 signalling pathway in hDF_LIF expressing the
mutant STAT3-K685R cDNA, revealed that STAT3 acetylation is
compulsory for phosphorylation of the residue tyrosine 705, and
that LIF-dependent JAK1/STAT3 constitutive phosphorylation
requires STAT3 acetylation (Fig. 2g). HN-CAF expressing
the mutant STAT3-K685R cDNA, lost proinvasive activity
(Supplementary Fig. 2e) and STAT3 phosphorylation,
independent of JAK1 activity (Supplementary Fig. 2f). Taken
together, these data demonstrate that STAT3 acetylation on
residue lysine 685 is compulsory for proinvasive ﬁbroblast
property.
DNMTs govern LIF-dependent ﬁbroblasts activation. Screening
using the small-molecule inhibitor library also identiﬁed
hypomethylating agents (DNA methylation inhibitors) as the
most potent molecules blocking HN-CAF and hDF_LIF matrix
remodelling (Fig. 1e, Supplementary Fig. 1c). We disclosed that
50-azacytidine (50-Aza), decitabine and zebularine, pyrimidine
nucleoside analogues of cytidine incorporated into DNA, where it
reversibly inhibits DNMT, interfered with CAF-dependent
SCC12 cell collective invasion (Fig. 3a). Therefore, we next
assessed the role of the DNMT protein family in LIF-dependent
constitutive ﬁbroblast activation in three-dimensional in vitro
organotypic invasion assays. Speciﬁc RNAi-dependent silencing
of DNMT1 expression in ﬁbroblasts (Supplementary Fig. 3a)
demonstrated that DNMT1 expression is required for
CAF-dependent matrix remodelling (Fig. 3b) and invasion of
SCC12 cells (Fig. 3c). DNMT1 is primarily implicated in the
maintenance of CpG methylation throughout development and
cell divisions, while DNMT3 role consists in de novo CpG
methylation31. Therefore, to assess a possible involvement of
DNMT3 in initiation of the contractile and proinvasive process of
the LIF-dependent ﬁbroblast activation, we investigated the
messenger RNA (mRNA) steady-state level of the DNMT
family after short-term LIF stimulation of hDF. We ﬁrst found
that mRNA steady-state level of DNMT3b, but not that of
DNMT1 or 3a, was signiﬁcantly induced after short-term LIF
stimulation of hDF (Fig. 3d). We second observed that DNMT3b
binds to STAT3 active form upon LIF stimulation (Fig. 3e);
therefore, the potential role for DNMT3b in induction of the
constitutive proinvasive activation by LIF in hDF was
investigated. Speciﬁc deletion of DNMT3b expression before
LIF stimulation resulted in blockage of LIF-dependent activation
of a proinvasive phenotype in hDF (Fig. 3f,g); whereas loss of
DNMT3b expression in CAF and in long-term activated hDF_LIF
had no effect on gel contraction (Supplementary Fig. 3b,c). Taken
together, these results demonstrate that DNMT3b governs the
LIF-dependent proinvasive ﬁbroblast activation, which in
HN-CAF is sustained by DNMT1. This explains why in
HN-CAF, which have undergone the activation step, mediated
by a LIF/DNMT3b signalling, targeting DNMT3b is ineffective,
while targeting DNMT1 blocks the proinvasive phenotype.
JAK1/STAT3 sustained activity is mediated by loss of SHP-1.
Having shown that restriction of the DNMTs catalytic activities
inhibits both the establishment and the maintenance of the
proinvasive phenotype of carcinoma- and LIF-activated ﬁbro-
blast, we ﬁrst investigated the molecular mechanisms underlying
the DNMT-dependent proinvasive ﬁbroblast activation. The
effect of 50-Aza on the JAK1/STAT3 constitutive signalling
pathway activity was thus assessed after treatment of HN-CAF
and LIF-activated ﬁbroblast. Inhibition of both STAT3 phos-
phorylation and acetylation was observed (Fig. 4a) potentially
consequent to inhibition of JAK1 phosphorylation on residue
tyrosine 1022 (Fig. 4a, Supplementary Fig. 4a), which reﬂects its
kinase activity32. JAK1 tyrosine 1022 phosphorylation is
controlled by a balance between JAK kinase transactivation and
dephosphorylation33. To address the functional role of 50-Aza in
the JAK1/STAT3 signalling activity and by consequence in
HN-CAF proinvasive ability, we hypothesized that a DNMT-
dependent epigenetic silencing regulates JAK1 phosphatase
expression. Thus HN-CAF were exposed to 50-Aza and then
to orthovanadate, a broad phosphatase inhibitor. Under such
experimental conditions JAK1 phosphorylation and both STAT3
phosphorylation and acetylation were rescued (Supplementary
Fig. 4b), which validated the working hypothesis. Since tyrosine-
protein phosphatase non-receptor type 6 (PTPN6), also known
as SHP-1 (Src homology region 2 domain-containing
phosphatase-1), is known to dephosphorylate a number of
tyrosine kinases including JAK1 (ref. 34), the possibility that
SHP-1 could regulate the proinvasive activity of HN-CAF in our
system was assessed. Indeed, speciﬁc SHP-1 inhibition by PTP
inhibitor 1 (PTP inh 1) restored the proinvasive property blocked
by the 50-Aza treatment (Fig. 4b). Subsequent analyses at the
molecular level demonstrated that SHP-1 re-expression induced
by 50-Aza treatment correlated with decreased JAK1/STAT3
activity in HN-CAF, and that inhibition of SHP-1 phosphatase
activity restored a constitutive JAK1/STAT3 signalling activity
(Fig. 4c). Furthermore, in both HN-CAF and hDF_LIF, inhibition
of both the proinvasive capacity (Supplementary Fig. 4c) and
JAK1/STAT3 signalling (Supplementary Fig. 4d,e) induced by
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loss of DNMT1 expression consequent to RNAi treatment was
rescued by speciﬁc RNAi targeting of SHP-1 expression. Taken
together, these data demonstrate that long-term activation of
proinvasive ﬁbroblast activity is sustained by constitutive
activation of the JAK1/STAT3 signalling pathway through a
DNMT1-dependent downregulation of the SHP-1 phosphatase
expression. At the initiation phase, LIF induces an enhanced
expression of DNMT3b and the loss of SHP-1 expression, which
a
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Figure 2 | P300 acetylates STAT3 for proinvasive CAF activity. (a) Representative images of H&E coloration of parafﬁn-embedded sections of SCC12 in
response to control hDF transfected with control siRNA (siLuc) or p300 (sip300) prior to control (veh.) or LIF stimulation. Scale bar, 100 mm (n¼ 3; mean
±s.d.; ***Po0.001). (b) Immunoblot of p300, AcSTAT3 and pSTAT3 in hDF transfected with RNAi control (siLuc) or targeting p300 (siP300#1 and #2)
before LIF stimulation. Immunoblot of STAT3 and tubulin as control. (c) Immunoblot of p300, AcSTAT3, pSTAT3 and STAT3 in hDF following
immunoprecitation of STAT3 on 24h LIF stimulation. Immunblot of p300 and tubulin in total lysate as control. (d) Immunoblot of pJAK1, AcSTAT3 and
pSTAT3 in hDF in presence or absence of C646 inhibitor followed by long-term control (veh.) or LIF stimulation. Immunoblot of JAK1, STAT3 and tubulin as
control. (e) Immunoblot of pJAK1, AcSTAT3 and pSTAT3 in control or long-term CTBP stimulated hDF. Immunoblot of JAK1, STAT3 and tubulin as control.
(f) Representative images of H&E colouration of parafﬁn-embedded sections of SCC12 in response to control hDF (veh.) and hDF_LIF overexpressing a
control (empty-GFP) or a wild-type STAT3 (STAT3-GFP) or acetylated-deﬁcient STAT3 mutant (STAT3-K685R-GFP). Scale bar, 100mm (I.I., invasion index;
n¼ 3; mean±s.d.; ***Po0.001). (g) Immunoblot of pJAK1, pSTAT3 and AcSTAT3 in hDF overexpressing a control vector (empty-GFP), a wild-type (WT)
STAT3 (STAT3-GFP) or acetylated-deﬁcient STAT3 mutant (STAT3-K685R-GFP) in response to long-term LIF stimulation. Immunoblot of JAK1, STAT3, and
tubulin as control.
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results in constitutive JAK1/STAT3 signalling pathway activity.
Accordingly blockage of DNMT3b expression, prior to LIF
stimulation, leads to inhibition of JAK1/STAT3 phosphorylation
and rescue of SHP-1 protein expression (Fig. 4d). Consistently
with our previous data, inhibition of p300 catalytic activity or loss
of p300 expression consequent to RNAi treatment before LIF
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Figure 3 | DNMTs controls proinvasive ﬁbroblasts’ activity. (a) Representative images of H&E colouration of parafﬁn-embedded sections of
SCC12 in response to CAF in the absence (Veh.) or presence of 50-Aza inhibitor (n¼ 3, I.I., invasion index, mean±s.d., ***Po0.001). Scale bar 100mm.
(b) Percentage of gel contraction by CAF transfected with siRNA control (siLuc) or targeting DNMT1 (siDNMT1#1, #2, #3, #4) (n¼ 3 in triplicate,
meanþ s.d., ***Po0.001). Bottom images show the contracted gels. (c) Representative images of H&E colouration of parafﬁn-embedded sections of
SCC12 in response to CAF transfected with siRNA control (siLuc) or targeting DNMT1 (siDNMT#1, #2, #3, #4) (n¼ 3, mean±s.d., ***Po0.001). Scale bar
100mm. (d) Quantiﬁcation of mRNA level of DNMT1, DNMT3a and DNMT3b in hDF following 48 h stimulation of LIF relative to control hDF (red dotted
line) (n¼ 3 in triplicate, meanþ s.d., ***Po0.001). (e) Immunoblot of AcSTAT3, DNMT3b and STAT3 in hDF cells overexpressing a control or a wild type
STAT3 or acetylated deﬁcient STAT3 mutant following STAT3 immunoprecipitation upon LIF stimulation. Immunoblot of pSTAT3, STAT3 and tubulin on
total lysates as control. (f) Representative images of H&E coloration of parafﬁn-embedded sections of SCC12 in response to hDF transfected with siRNA
control (siLuc) or targeting DNMT3b (siDNMT3b#1 and #2) and subsequently long-term control- (Veh.) or LIF-activated hDF (n¼ 3, mean±s.d.,
***Po0.001). Scale bar 100 mm. (g) Immunoblot of DNMT3b in hDF activated or not by LIF transfected with siRNA control (siLuc) or targeting DNMT3b
(siDNMT3b#1, #2, #3, #4). Immunoblot of tubulin as control.
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Figure 4 | Epigenetic-dependent sustained JAK1/STAT3 signalling in CAF. (a) Immunoblot of pJAK1, pSTAT3 and AcSTAT3 in CAF after 7-days
treatment in the presence or absence of 50-Aza inhibitor at 10 and 3 mM ﬁnal concentration. Immunoblot of JAK1, STAT3 and tubulin as control. (b)
Representative images of H&E coloration of parafﬁn-embedded sections of SCC12 in response to CAF following 50-Aza inhibitor alone or in combination
with PTP inhibitor 1 (n¼ 3, mean±s.d., ***Po0.001). (c) Immunoblot of DNMT1, pSHP-1, SHP-1, pJAK1, pSTAT3 and AcSTAT3 in CAF following 50-Aza
inhibitor alone or in combination with PTP inhibitor 1. Immunoblot of JAK1, STAT3 and tubulin as control. (d) Immunoblot of DNMT3b, SHP-1, pJAK1,
pSTAT3 and AcSTAT3 in hDF activated or not by LIF transfected with siRNA control (siLuc) or siRNA targeting DNMT3b (siDNMT3b#1, #2). Immunoblot
of JAK1, STAT3 and tubulin as control. (e) Schematic illustration of the PTPN6 gene structure and the regions analysed by bisulﬁte sequencing. The PTPN6
gene has two alternative promoters. We restricted our analysis to Promoter 1 since Promoter 2 is mostly active in the haematopoietic lineage. Vertical lines
in Region 1 and Region 2 indicate the position of the CpG dinucleotides. (f) Bisulﬁte-sequencing results in two regions of the PTPN6 promoter (R1 and R2) in
hDF transfected with control RNAi (siLuc) and RNAi targeting DNMT3b (siDNMT3b#1 and #2) and subsequently long-term control ( ) or LIF-activated
(þ ). Each line represents an individual sequence. Open and closed circles denote unmethylated and methylated CpG dinucleotides, respectively.
Donut charts summarize the global proportion of methylated CpG with the percentage in the center (n¼ 2, Po0.0001, two-tailed Fisher’s exact test).
(g) Representative images of H&E coloration of parafﬁn-embedded sections of SCC12 in response to CAF overexpressing control vector (GFP) or SHP-1
gene (SHP-1_GFP) (n¼ 3, mean±s.d., ***Po0.001). (h) Immunoblot of SHP-1, pJAK1, pSTAT3 and AcSTAT3 in CAF overexpressing control vector (GFP)
or SHP-1 gene (SHP-1_GFP). Immunoblot of JAK1, STAT3 and tubulin as control.
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stimulation inhibits the loss of SHP-1 expression in hDF
(Supplementary Fig. 4f,g). A possible explanation is that LIF,
through a DNMT-dependent pathway, regulates the methylation
status of the SHP-1 promoter. To address this possibility, we
analysed by bisulﬁte sequencing the two regions R1 and R2 of the
PTPN6 promoter 1 (ref. 35) rich in CpG dinucleotides (depicted
in Fig. 4e). Strikingly, long-term LIF-treated hDF compared with
untreated controls, presented hypermethylation of the PTPN6
promoter, a DNMT3b- (Fig. 4f, Supplementary Fig. 4h)
dependent modiﬁcation that was hampered by siRNA-mediated
knockdown of DNMTs during LIF stimulation. Accordingly,
transgenic expression of SHP-1 in HN-CAF was sufﬁcient to
block the proinvasive capacity of these cells (Fig. 4g) and to
inhibit their JAK1/STAT3 signalling pathway activity (Fig. 4h).
Accordingly, SHP-1 was undetectable in CAF from multiple
carcinoma origins compared with three primary hDF
(Supplementary Fig. 4i) and regions 1 and 2 of PTPN6
promoter 1 of human CAF were hypermethylated compared
with the hDF PTPN6 promoter (Supplementary Fig. 4j). These
results establish that a LIF/p300/DNMT signalling governs the
initial step of JAK1/STAT3 constitutive activation through SHP-1
silencing. Once this epigenetic repression is established, targeting
DNMT3b has no effect, while targeting DNMT1 inhibits the
proinvasive phenotype of CAF.
Phenotypic and molecular constitutive reversion of CAF.
Ruxolitinib, an FDA approved JAK1/2 pharmacological inhibitor,
targets proinvasive tumour microenvironment modiﬁcations
by transiently inhibiting human CAF contractility16. Having
demonstrated here that DNMT1 supports constitutive
JAK1/STAT3 activation and proinvasive activity of HN-CAF,
we hypothesized that treatment of activated ﬁbroblasts with
50-Aza could permanently revert the activated phenotype. To test
such an idea, activated ﬁbroblasts were cultured for 7 days in the
presence of either Ruxolitinib or 50-Aza. After removal of the
inhibitors, the molecular activity of the JAK1/STAT3 signalling
pathway was measured for 5 days, and the contractile activity of
the treated cells was monitored for additional 45 days in collagen
gel (Fig. 5a). HN-CAF treated with Ruxolitinib restored STAT3
phosphorylation 2 days after drug removal, while SHP-1
expression was not affected (Supplementary Fig. 5a). 50-Aza
treatment resulted in a transient 3-day decrease of STAT3
phosphorylation, SHP-1 expression was ﬁrst induced on DNMT1
inhibition, but restoration of the STAT3 activity correlated with
the loss of SHP-1 protein (Supplementary Fig. 5b). Taken
together, these data indicate that in HN-CAF the effects of both
Ruxolitinib and 50-Aza are transient. Because both drugs act at
different signalling levels to regulate the JAK1/STAT3 signalling
pathway, possible synergistic action of the two compounds was
explored. Combined 7-day Ruxolitinib and 50-Aza treatment of
activated ﬁbroblasts resulted in long-term abrogation of the
JAK1/STAT3 phosphorylation and rescued SHP-1 protein
expression (Supplementary Fig. 5c). Further, such long-term
abrogation of the JAK1/STAT3 signalling pathway activity was
conﬁrmed using hDF_LIF (Supplementary Fig. 5d) by dual
inhibitor treatment. We next assessed whether the combined
treatment could revert activated ﬁbroblasts into a permanent low-
contractile and non proinvasive hDF phenotype. While HN-CAF
and hDF_LIF treated with one inhibitor initially showed
signiﬁcant reduction of contractile capacity, no signiﬁcant
difference was observed at day 15 compared with the untreated
counterparts (Fig. 5b, Supplementary Fig. 5e). On the contrary,
on combined treatment, the activated ﬁbroblasts completely and
permanently lost all capacity to contract the collagen lattices
(50-day assays) that became indistinguishable from the hDF
counterparts (Fig. 5b, Supplementary Fig. 5e). Similar abrogative
effects were observed after a 21-day treatment (Supplementary
Fig. 5f,g). Interestingly, abrogation of the proinvasive phenotype
was observed with carcinoma-, LIF- and TGFb-activated
ﬁbroblasts even after removal of the two inhibitors. In cells
exposed to only one of the two inhibitors, the abrogative effect
was reversed 5 days after the drug removal (Fig. 5c). Also, in an
organotypic model of breast carcinoma, Br-CAF promoted
collective invasion capacity in the MDA-MB-468 carcinoma cell
line that was abrogated by the combined 50-Aza and Ruxolitinib
treatment of the Br-CAF (Fig. 5d). Taken together, these data
demonstrate that in hDF, LIF induces an epigenetic-dependent
constitutive activation of the JAK1/STAT3 signalling pathway
that governs the proinvasive CAF cell ability. Such epigenetic
activation is abrogated on the long term by treatments combining
JAK1 and DNMT inhibitors. The potential therapeutic effect
of targeting the DNMT and JAK pathway during breast
carcinomagenesis was evaluated in vivo. Thus, mouse dermal
ﬁbroblasts (mDF), isolated from back skin of Balb/C mice, were
activated in vitro by LIF, then submitted to treatment with either
one of each inhibitors or a combination of both. Treated mDF
were co-implanted in the forth mammary fat pad of BALB/c
female mice together with the 67NR mouse mammary carcinoma
cell line, that neither invades from the primary tumour, nor
activates ﬁbroblasts in vitro and in vivo16 (Fig. 6a). Thirty days
after co-implantation, the mice were killed, and the 67NR
cell-invasive capacity and tumour ECM remodelling were
analysed by immunohistochemistry. 67NR cells, from the
primary tumour bulk (T) invaded the adjacent tissue exclusively
when co-implanted with LIF-activated mDF, which contrasted
with the behaviour of 67NR injected either alone or co-implanted
with control mDF (mDF_Veh.). Treatment of mDF_LIF with one
inhibitor reduced the onset of a proinvasive microenvironment,
while treatment combining both inhibitors restored the non-
invasive 67NR cell phenotype (Fig. 6b,c, left panels). The invasive
behaviour of 67NR cells correlated with an excessive tumour
ECM remodelling disclosed by Picrosirius Red staining and
orthogonal light visualization (Fig. 6c, middle and right panels,
and Fig. 6d). Taken together, these data indicate that
LIF-activated ﬁbroblasts induce onset of a proinvasive tumour
microenvironment in vivo, in a syngenic and orthotopic mice
model of breast cancer.
STAT3 and SHP-1 inverse expression in human carcinomas.
To conﬁrm the in vitro ﬁndings with ex vivo observations, an
immunohistological analyses of STAT3 phosphorylation and
acetylation together with SHP-1 expression were performed in
100 human carcinoma samples from head and neck (n¼ 50) and
lung (n¼ 50) cancers (Fig. 7a, Supplementary Fig. 6a). The levels
of AcSTAT3 detected in lung (Fig. 7b) and head and neck
(Fig. 7c) was consistently opposite to SHP-1 expression, which
establishes a strong inverse correlation between STAT3-K685
acetylation and SHP-1 expression (r2¼  0.87 for head and neck;
r2¼  0.55 for lung carcinomas; Fig. 7d). Thus the ex vivo data
are consistent with the in vitro evidence revealing that STAT3
acetylation leads to SHP-1 downregulation in stromal ﬁbroblasts.
No signiﬁcant difference between phosphorylation and acetyla-
tion of STAT3 in the tumour stroma of both head and neck
and lung tumours biopsies was observed, which corroborates
the in vitro evidence that STAT3 acetylation is compulsory
for phosphorylation of the STAT3 tyrosine 705 residue
(Supplementary Fig. 6a–c). Next, the quick scores obtained from
each variable were considered for the design of a predictive
model. A principal component analysis was done to highlight
dispersed values and build a clean set of measurements avoiding
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Figure 5 | Phenotypic and molecular reversion of CAF. (a) Schematic representation of the experimental conditions for long-term phenotypic and
molecular reversion of the proinvasive property of activated ﬁbroblasts. After inhibitors treatment for 7 or 21 days, cells are embedded in matrix for a
50-day gel contraction assay, assayed every day for a period of 5 days for molecular analysis, and assayed at day 5 after inhibitors removal for proinvasive
ability. (See also Supplementary Fig. 5). (b) Percentage of gel contraction of hDF and CAF for a period of 50 days following a 7-day treatment of either
Ruxolitinib or 50-Aza or both inhibitors together. (c) Representative images of H&E coloration of parafﬁn-embedded sections of SCC12 in response to CAF,
hDF_LIF and hDF_TGFb1, 5 days after a period of 7-day treatment of Ruxolitinib or 50-Aza or both inhibitors together (n¼ 3, mean±s.d., ***Po0.001).
Scale bar 100mm. (d) Representative images of H&E colouration of parafﬁn-embedded sections of MDA-MB-468 human breast cancer cell line in response
to breast CAF 5 days after a period of 7-day treatment of Ruxolitinib or 50-Aza or both inhibitors together (n¼ 3, mean±s.d., ***Po0.001).
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Figure 6 | Stromal DNMT and JAK favour tumour invasion in vivo. (a) Schematic representation of the experimental conditions used for in vivo cell
co-implantation into the mammary fat pad of 8-week-old BALB/c female mice. 67NR mouse breast carcinoma cells were co-injected together with
LIF preactivated mDF and treated with inhibitors. (b) Graphic representation of tumour formation induced by 67NR cells alone or in the presence of
LIF-preactivated mDF. Total numbers of mice bearing tumours after single or combined inhibitor treatment are shown. (c) H&E coloration of parafﬁn-
embedded sections of primary tumours isolated from mice (left panels) showing 67NR cells invading from the primary tumour (T) into the adjacent tissue
(aT) (black arrow). Picrosirius Red staining visualized by both parallel (middle panels) and orthogonal (right panels) light showing tumour ECM remodelling
at the areas invaded by the tumoral 67NR cells. Scale bars, 200 and 100mm for  20 and 40X magniﬁcations, respectively. (d) Quantiﬁcation of
Picrosirius Red staining using ImageJ software. Percentage of threshold area is shown (mean±s.d.; *Po0.05).
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these values. Twenty six values were eliminated from the set.
Scatter-plots were made to calculate the correlation matrix for
each couple of variables for both the complete and the cleaned
set of measurements (Supplementary Table 2A). Correlation
coefﬁcients are widely acceptable especially for the cleaned set,
suggesting the possibility to deﬁne a reliable predictive model.
Using linear multivariate logistic regressions three predictive
models were thus obtained (Supplementary Table 2B). In silico
values generated from these models are highly correlated with the
ex vivo values. Furthermore, the ‘SHP-1Bac-STATþ p-STAT’
model resulted to be relevant and able to predict the SHP-1 level
by scoring STAT3 phosphorylation and acetylation only with
high level of conﬁdence (Supplementary Fig. 6d).
Discussion
CAF are responsible for the onset of the proinvasive tumour
microenvironment, which favours carcinoma cell dissemination
from the primary tumour. Interestingly, the proinvasive proper-
ties of CAF remain activated even after their isolation from
tumours and propagation in vitro2,9,10,16,36–38. Here, we show
that such permanently activated proinvasive status of CAF,
isolated from head and neck, lung and breast carcinomas, results
from the LIF-mediated persistent activation of the JAK1/STAT3
signalling pathway, which regulates acto-myosin contractility and
confers on them the proinvasive capacity of digging tracks within
the ECM that are subsequently used by the tumour cells to
collectively invade9,15. Constitutive activation of the JAK1/STAT3
signalling pathway is a process frequently observed in tumour
cells39,40. It involves either genetic mutations activating the
GP130-IL6ST receptor41, or the JAK2 kinase42 or secretion of
growth factors and cytokines mediating an autocrine activation of
the signalling pathway43. While occurrence of oncogenic
mutations in CAF is still matter of debate27,44, in our case, any
possible involvement of secreted factors from both CAF and
LIF-activated ﬁbroblasts can be excluded (Fig. 1c,d). Activated
ﬁbroblasts isolated form tumours or ﬁbrotic tissues present a
globally hypomethylated DNA proﬁle that strikingly contrasts
with a hypermethylated pattern of the promoters of tumour-
suppressor genes such as Thy1, tgfbr2 or PTEN24,45–50. Moreover,
epigenetic modiﬁcations are considered a crucial step in the
constitutive ﬁbroblast activation in a mouse model of kidney
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Figure 7 | Inverse correlation of AcSTAT3 and SHP-1 expression. (a) AcSTAT3, pSTAT3 and SHP-1 immunohistological staining in human head
and neck (n¼ 50) and lung (n¼ 50) carcinomas. Scale bar, 100mm. (b) Quantiﬁcation of mean Quick Score (QS) for SHP-1, both in the stroma
and the tumour bulk, in lung carcinomas decorated with high- and low-acetylated STAT3 shown in a. (c) Quantiﬁcation of mean Quick Score (QS)
for pSTAT3, in the tumour bulk, in lung carcinomas decorated with high and low acetylated STAT3 shown in a. (d) Quantiﬁcation of mean QS for
SHP-1, both in the stroma and the tumour bulk, in head and neck carcinomas decorated with high- and low-acetylated STAT3 tumours shown in a.
(e) Quantiﬁcation of mean Quick Score (QS) for pSTAT3, in the tumour bulk, in head and neck carcinomas decorated with high- and low-acetylated STAT3
shown in a. (f) Plot of mean QS form AcSTAT3 (x axis) and SHP-1 (y axis) showing a negative correlation between Acetylated STAT3 and SHP-1 detection
in lung (blue) and head and neck (red) carcinomas.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10204 ARTICLE
NATURE COMMUNICATIONS | 6:10204 | DOI: 10.1038/ncomms10204 |www.nature.com/naturecommunications 11
ﬁbrosis12. Consistent with such observations, we have identiﬁed
the DNMT family epigenetic modiﬁers as regulators of the
proinvasive CAF activity that acts on the JAK1 and STAT3
constitutive activation. In this context, we provide evidence
that LIF induces an initiation phase that requires DNMT3b
transcriptional expression and its association with AcSTAT3 to
promote methylation of the PTPN6 tyrosine phosphatase
promoter. Subsequently, the DNMT1-dependent replication
methylation of the PTPN6 promoter maintains silent the SHP-1
expression, which causes constitutive tyrosine phosphorylation of
JAK1 resulting in ﬁbroblast activation. Epigenetic regulation of
the JAK1/STAT3 pathway has been suggested in tumour
cells19,22,51,52. However, we demonstrate for the ﬁrst time that
in cancer epigenetic downregulation of SHP-1 sustains the
proinvasive activity of the stromal ﬁbroblasts. Interestingly, this
observation is corroborated by the strong inverse correlation
existing between detection of acetylated STAT3 and expression of
SHP-1 observed in human tissues obtained form head and neck
and lung tumour specimens. In light of our results, we propose
that PTPN6, a tumour-suppressor gene in leukaemia and
lymphoma, acts as a ﬁbrotic suppressor gene in CAF from head
and neck, lung and breast cancers.
We further disclose a crucial role for p300 HAT in proinvasive
HN-CAF phenotype (Fig. 2). Indeed, the transcriptional co-
activator p300 has been implicated in diverse biological functions,
including tissue ﬁbrosis53, and its catalytic acetyltransferase
activity is enhanced in ﬁbroblasts in response to TGFb (ref. 44)
and in tumour cells by the LIF or IL6 cytokines54. In our system,
speciﬁc inhibition of p300 abolishes the LIF- and carcinoma-
associated proinvasive ﬁbroblast activity, suggesting that, likewise
in several human diseases55, in stromal ﬁbroblasts p300 and its
homologue CBP possess distinct functions. Experimental
evidences attribute a clear role for both p300 and CBP in
tumorigenesis as tumour-suppressor genes in haematological
tumours and through regulation of tumour suppressing
signalling pathways, such as TGFb and p53, in cancer cells56.
Our results disclose a procarcinogenic function for p300.
Indeed, p300 activation by inﬂammatory cytokines leads to
permanent JAK1/STAT3 signalling activation through the
DNMT3b-dependent SHP-1 tyrosine phosphatase silencing and
proinvasive stromal ﬁbroblast initiation.
DNA epigenetic modiﬁcation is a reversible process. Reversion
can be induced by treatments with the 50-Aza that degrades
DNMT57. However, in patients with myelodisplastic syndromes,
re-expression of tumour-suppressor genes consequent to
treatment with 50-Aza or decitabine is transient and
concomitant with reversion of the methylation proﬁles58. In our
system, a 7-day treatment on both HN- and Br-CAF or hDF_LIF
combining both 50-Aza and the JAK1/2 inhibitor Ruxolitinib
reverts the proinvasive properties of activated ﬁbroblasts on the
long term. Association of both compounds is mandatory for such
a long-term effect, because treatments using each single-chemical
compounds only transiently inhibit the CAF-dependent matrix
remodelling, SCC12 cells invasion and SHP-1 protein expression.
It is conceivable that the passive DNA demethylation induced by
50-azacytidine31 is not sufﬁcient to permanently revert the CAF
phenotype, whereas active genomic demethylation, through
replacement of modiﬁed cytosine in the absence of cell
division59 may explain such a prolonged effect of the combined
inhibitor treatment. Indeed, BMP7-induced inhibition of kidney
ﬁbrosis is mediated by an active genomic Tet3-dependent Rasal1
promoter demethylation60. Hesson et al.61, suggested that
nucleosome reassembly is a crucial step that dictates the
transient efﬁcacy of DNMT inhibitors. We therefore
hypothesize that inhibition of DNMT activity, together with
JAK inhibition may lead to histone modiﬁcation, such as
acetylation and methylation, resulting in the inhibition of
nucleosome reassembly within the SHP-1 promoter.
In conclusion, our work establishes that acquisition and
long-term maintenance of head and neck, lung or breast CAF
proinvasive ability relies on a two-step mechanism. In hDF, LIF
initiates this process through STAT3 acetylation by p300 and
DNMT3b-dependent methylation of the PTPN6 promoter, which
is followed by a long-term maintenance phase mediated by a
DNMT1-dependent loss of SHP-1 expression and JAK1 kinase
constitutive activity. In light of our results obtained by combining
the use of 50-Aza and Ruxolitinb, both drugs approved by the
Food and Drug administration, we demonstrate phenotypical and
molecular reversion of activated ﬁbroblasts into ‘normal’
ﬁbroblast-like cells and we propose that such treatment might
represent an attractive approach to inhibit the onset of the
proinvasive tumour microenvironment in cancer.
Methods
Cell culture. Human primary dermal ﬁbroblasts (hDF), MDA-MB-468 and
human HEK293 Phoenix cells were maintained in DMEM supplemented with
10% FCS (fetal calf serum). Human CAF isolated from patients with head and
neck, lung and breast cancers were cultured in DMEM supplemented with 10%
FCS and insulin-transferrin-selenium (#41400-045; Invitrogen, Carlsbad, CA).
SCC12 cells were cultured in FAD media, as described in Gaggioli et al.9.
Long-term LIF and TGFb1-activated ﬁbroblasts (hDF_LIF and hDF_TGFb1)
have been performed in DMEM supplemented with 0.5% FCS containing
2 ngml 1 ﬁnal concentration of human recombinant proteins for 7 days. Next,
activated-hDF was cultured for 15 days (otherwise stated) in 0.5% FCS media
before experiments (as described in Supplementary Fig. 1a).
Cytokines and neutralizing antibodies and inhibitors. TGFb1 was purchased
from Peprotech (#100-21, Peprotech, Rocky Hill, NJ) and was used at 2 ngml 1;
recombinant human LIF was purchased from Millipore (#LIF1005,Millipore,
Billerica, MA), and was used at a concentration of 2 ngml 1. LIF neutralizing
antibody (AB-250-NA, R&D, Minneapolis, MN) was used at 10 mgml 1.
Neutralizing antibodies were incubated for 1 h with CM before experiments. The
following inhibitors were used in this study: Pyridone 6 (#42009, Calbiochem, Los
Angeles, CA) was used at 5 mM, Ruxolitinib (#1598, Axon medchem, Groningen,
The Netherlands) at 10mM, 50-Aza (#A2385, Sigma, Saint Louis, USA) was used
daily at 2.5 mM, PTP inh 1 (#540200, Millipore, Billerica, MA) at 10 mM, Sodium
Orthovanadate (#567540, Millipore, Billerica, MA) at 1mM, C646 (#SML002,
Sigma, Saint Louis, USA ) and CTPB (#sc- 202558, Santa Cruz, Biotechnology,
Santa Cruz, CA) at 25 mM. A list of the concentrations used for the inhibitors/
activators in Fig. 1d,e is provided in Supplementary Table 1.
RNAi transfections. Cells were plated at 60% conﬂuence and subjected to
transfection the following day using Dharmafect 3 (#T-2002-02; Dharmacon, Inc.,
Lafayette, CO) at 100 nM ﬁnal concentration of RNAi. For long-term activation
studies, ﬁbroblasts were transfected once at day 0, stimulated with recombinant
cytokines from day 1 to day 7, retransfected at day 8, and maintained in 0.5%
medium until day 15 for extracellular matrix remodelling, organotypic invasion
assays and protein extraction. RNAi sequences are listed below:
p300 #1—50-GGACUACCCUAUCAAGUAA-30
p300 #2—50-GACAAGGGAUAAUGCCUAA-30
HDAC3 #1—50-AACAAGAUCUGUGAUAUUG-30
HDAC3 #2—50-GGAAUGCGUUGAAUAUGUC-30
HDAC3 #3—50-GCACCCGCAUCGAGAAUCA-30
HDAC3 #4—50-AAAGCGAUGUGGAGAUUUA-30
DNMT1 #1—50-GCACCUCAUUUGCCGAAUA-30
DNMT1 #2—50-AUAAAUGAAUGGUGGAUCA-30
DNMT1 #3—50-CCUGAGCCCUACCGAAUUG-30
DNMT1 #4—50-CGACGACCCUGACCUCAAA-30
DNMT3b #1—50-ACGCACAGCUGACGACUCA-30
DNMT3b #2—50-UUUACCACCUGCUGAAUUA-30
DNMT3b #3—50-CGAAAUAACAACAGUGUCU-30
DNMT3b #4—50-GCUCUUACCUUACCAUCGA-30 .
Organotypic invasion assays and matrix remodelling assays. For Organotypic
invasion assays, 5 105 ﬁbroblasts were embedded in 1-ml matrix gel. After 1 h at
37 C, matrix gel were overlaid with 5 105 SCC12 cells and lifted at the cell-air
interface 24 h later for 5 days, the cultures were then ﬁxed, embedded in parafﬁn
blocks, sectioned and stained for invasion index quantiﬁcation using ImageJ30.
For gel contraction assay, 25 103 cells were embedded in 100 ml of matrix gel and
seeded in triplicate into 96-wells plate. After 1 h at 37 C, matrix gels were overlaid
with 100 ml of 0.5% FCS medium (with indicated cytokines or inhibitors) and
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changed every 2 days. At day 6, the relative diameter of the well and the gel were
measured using ImageJ. The percentage of gel contraction was calculated using the
formula 100 (well diameter gel diameter)/well diameter.
Antibodies. Antibodies against STAT3 (#9139; 1/1,000), pY705-STAT3
(#9145; 1/1,000), ac-K685 STAT3 (#2523; 1/1,000), SMAD2 (#3122; 1/1,000),
pSer465/467-SMAD2 (#3108; 1/1,000), pY1022/1023-JAK1 (#3331; 1/200), JAK1
(#3332; 1/500), MLC2 (#3672; 1/500) and pThr18/19-MLC2 (#3674; 1/500) were
purchased from Cell Signalling (Cell SignalingTechnology, Beverly MA), a-tubulin
from sigma (T4026, Sigma, Saint Louis, MO; 1/5,000); SHP-1 (#sc-7289, 1/ 500 for
western blot analysis), DNMT1 (#sc-20701; 1/1,000), DNMT3b (#sc-130740;
1/1,000) from Santa Cruz Biotechnology (Santa Cruz Biotechnology, Santa Cruz,
CA) and SHP-1 (#ab2020; 1/200 for immunohistochemical staining) from Abcam
(#ab2020, Abcam, Cambridge, UK) from Bethyl Laboratories (Bethyl Laboratories,
Montgomery, TX, USA).
Western blots and Co-immunoprecipitation analysis. For immunoblotting
analysis, cells were lysed on ice in lysis buffer (25mM Tris (pH 6,8), 2% SDS,
5%glycerol, 1% b-mercaptoethanol, 0.01% bromophenol blue). Equal amounts of
protein from each sample were loaded on SDS–PAGE, separated, and transferred
onto nitrocellulose. The immunoblots were blocked by incubation in 5% bovine
serum albumin, 10mM Tris-HCl (pH 7.5), 500mM NaCl, 0,1% Tween 20 for
30min at room temperature, probed with speciﬁc antibodies and then with
secondary antibodies using common classical methods. Immunodetection was
performed using chemiluminescent HRP substrate (#WBKLS0500, Millipore,
Billerica, MA). Uncropped western blots are shown in the Supplementary
Information section and labelled as Supplementary Fig. 7.
For co-immunoprecipitation analysis, cells were lysed on ice in modiﬁed RIPA
buffer (50mM Tris pH 7.4 150mM NaCl, 1%NP-40, 0.1% SDS, 0.5% SD
Dexoxycholate, 5mM NaF, 2.5mM Nappi, and protease inhibitor (#04693159001,
Roche)) for 30min and isolated by centrifugation (30min, 10,000 g, 4 C).
Supernatants were precleared with Magna CHIP protein G bead (#16-662,
Millipore) and the cleared lysate incubated with primary antibody overnight at
4 C. Immune complexes were captured by adding 35 ml of protein G magnetic
beads, rotated for 1 h at 4 C and washed three times with lysis buffer (without SDS,
sodium deoxycholate and protease inhibitors). Immunoprecipitation products were
separated by SDS–PAGE.
RT–qPCR analysis. RNA isolation was performed using RNeasy Mini kit
(#217004, Qiagen, Turnberry Ln, Valencia, CA) according to the manufacturer’s
instructions. Reverse transcription (RT) of 500 ng RNA by Superscript II reverse
transcriptase (#18064-014, Invitrogen, Carlsbad, CA) was followed by real-time
PCR using Fast SYBR Green Master Mix (#18064-014; Applied Biosystems, Foster
City, CA) and performed on a Step One Plus Real-Time PCR system (Applied
Biosystems, Foster City, CA).
Primers sequences are listed as follows:
DNMT1: sense, 50-CCAAAGCCCGAGAGAGTGCCTCAG-30 and antisense,
50-CCTTAGCAGCTTCCTCCTCCTT-30 ;
DNMT3a: sense, 50-CTGAAGGACTTGGGCATTCAG-30 and antisense,
50-CACCATGCCCACCGTGA-30 ;
DNMT3b: sense, 50-TACACAGACGTGTCCAACATGGGC-30 and antisense,
50-GGA-TGC-CTTCAGGAATCACACCTC-30 ;
GAPDH: sense, 50-ACCCAGAAGACTGTGGATGG-30 , and antisense,
50-TCTAGACGGCAGGTCAGGTC-30.
Relative expression of the respective gene was determined after normalization to
GAPDH and calculated with the following formula: relative expression
level¼ 2ddCT.
Statistical analysis. Student’s t-test was performed for statistical analysis of
invasion assay, gel contraction assay, and quantitative PCR (qPCR) results.
***Po0.001, **Po0.01 and *Po0.05. Error bars are þ s.d. Pearson’s correlation
coefﬁcient was used to assess the relationship between pSTAT3, AcSTAT3 and
SHP-1 quick score within human samples.
In silico linear multivariate logistic regression. Quick score experimental values
from 100 carcinomas were considered to design a model allowing predicative
values depending of 2 others. A principal component analysis was done to
highlight dispersed measurements and build a clean set (n¼ 74) suitable for
building the model. Correlations between the variables were checked and a
linear multivariate logistic regression achieving to determine the model. Statistical
analyses were performed using R software62.
Immunohistochemical staining and quantiﬁcation methods. Fifty head and
neck and 50 lung tumour biopsies were ﬁxed (3.7% formaldehyde in PBS) for 4 h
and transferred to 70% ethanol (24 h), embedded in parafﬁn wax and sectioned
at 7 mm. After deparafﬁnation, microwave antigen retrieval was performed in
Na-citrate buffer (10mM, pH6; 5min at 900W, 10min at 150W and 30min at
room temperature) for SHP-1 staining, and in EDTA buffer (1mM, PH8, 5min at
900W and 25min at 150W) for DNMT3b, pSTAT3 and AcSTAT3 staining.
Sections were washed three times in PBS (5min per wash) before endogenous
peroxidase activity was blocked in 1% H2O2 for 10min and washed three times in
PBS. After incubation in blocking buffer for 2 h (10% serum (S-5000, S-1000;
Vector, Burlingame, CA); 0.3% Triton X100 in PBS), sections were incubated with
primary antibody diluted 1:50 in blocking buffer overnight at 4 C. After three
washes in PBS, sections were incubated with biotinylated secondary antibody
(#BA-1000 Vector, Burlingame, CA) diluted 1:400 in PBS for 30min and washed
three times in PBS. Samples were then processed using Vectastain ABC kit
(#PK4001, Vector, Burlingame, CA) and DAB peroxidase substrate kit (#SK4100,
Vector, Burlingame, CA) according to manufacturer’s instructions. Sections were
next counterstained with haematoxylin for 5 s, rinsed in water, blued 10 s in 0,08%
ammonia water, dehydrated, cleared and mounted with cover clips. Two authors,
blinded to each other’s assessment, scored the slides using the Quick Score
method16 to determine pSTAT3, AcSTAT3, DNMT3b and SHP-1 status within the
tumour bulk and stroma. The protocol was approved by the local ethic committee
of the Nice University Hospital. All patients signed an informed consent for
inclusion into the research project.
Picrosirius Red stain and quantiﬁcation. Picrosirius Red stain was achieved
through the use of 5-mm parafﬁn sections stained with 0.1% Picrosirius Red
(Direct Red80, Sigma-Aldrich) and counterstained with Weigert’s haematoxylin to
reveal ﬁbrillar collagen. The sections were then serially imaged using with an
analyser- and polarizer-oriented parallel and orthogonal to each other. Microscope
conditions (lamp brightness, condenser opening, objective, zoom, exposure time
and gain parameters) were constant throughout the imaging of all samples.
A minimal threshold was set on appropriate control sections for each experiment
in which only the light passing through the orthogonally oriented polarizers
representing ﬁbrous structures (that is, excluding residual light from the black
background) was included. The threshold was maintained for all images across all
conditions within each experiment. The area of the transferred regions that was
covered by the thresholded light was calculated and at least ﬁve  20 ﬁeld per
condition were averaged together (Image J software).
Orthotopic syngenic tumours xenograft in BALB/c mice. Eight-week-old female
BALB/c mice were anaesthetized using ketamine and xylazine by peritoneal
injection. Skin was incised and 106 67NR were co-injected into the right fourth
mammary fat pad in 10ml PBS with or without 106 BALB/c dermal ﬁbroblast
(isolated from the back skin of 6- to 10-week-old BALB/c mice) treated as
described in Fig. 6a. Mice were killed 30 days post injection, primary tumours were
removed. After excision and 12 h of ﬁxation in 3.7% neutral-buffered formalin at
25 C, tumours were parafﬁn-embedded via an ethanol–xylene dehydration series,
before being sliced into 5-mm sections and stained with haematoxylin and eosin or
Picrosirius Red. The protocol was approved by the local committee of the host
institute and by the Institutional Animal Care and Use Committee (CIEPAL AZUR
committee, MESR number 2015051917125051) at the University of Nice-Sophia
Antipolis, Nice, France.
DNMT activity assay. Episeeker DNMT activity quantiﬁcation kit (#ab113467,
Abcam, Cambridge, UK) was used to assess DNMT activity on 10 mg of nuclear
proteins (nuclear extracts were prepared using the EpiSeeker Nuclear Extraction
Kit (#ab113474, Abcam, Cambridge, UK)) following manufacturer’s speciﬁcations.
Plasmids constructs. pcDNA5-mSTAT3-K685R (in which K685 is mutated from
AAG (K) to AGG (R)) was derived from the wild-type pCDNA5-mSTAT3-GFP-
FRT expression vector (which was a gift from the laboratory of Dr. Mu¨ller-Newen)
using the Quick Change II site-directed mutagenesis kit (Agilent Technologies,
Santa Clara, CA, USA). The sequence of the oligonucleotide primers used are:
STAT3-K685R-Forward: 50-GAGGAGGCATTTGGAAGGTACTGTAGGCCC
GAG-30 ; and STAT3 K685R-Reverse: 50-CTCGGGCCTACAGTACCTTCCAAAT
GCCTCCTC-30 and constructs were then coupled to GFP. Following constructs
veriﬁcation by nucleotide sequencing, the STAT3 (wild-type and K685R) fragments
were excised from pcDNA5 by Pme1 and BamH1 digestion and directionally
cloned into pBabe retroviruses expression vectors (containing the puromycin
resistance gene as a selectable marker) digested with NaeI and BamH1.
SHP-1 cDNA was isolated from hPF by RT–PCR and subcloned into a pBabe
retrovirus expression vector.
Production of recombinant retroviruses. Phoenix cells were transiently
transfected with 1 mg of the previously described vectors using calcium phosphate
mediated transfection using classical procedures. Six hours after transfection, cells
were washed with PBS and complete media was added. The day after, media was
replaced by a heat-inactivated serum medium and cells were moved to 32 C for
24 h. Forty-eight hours post transfection clariﬁed supernatents (retroviral particles)
were collected and used to infect either hDF or CAF. Retrovirus infection was
performed in the presence of 5 mgml 1 polybrene. Stably transduced cells were
selected with 5 mgml 1 puromycin.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10204 ARTICLE
NATURE COMMUNICATIONS | 6:10204 | DOI: 10.1038/ncomms10204 |www.nature.com/naturecommunications 13
Bisulﬁte sequencing. Genomic DNA was extracted with the QIAamp DNA Blood
Mini Kit (Qiagen). Bisulﬁte sequencing was conducted with the EZ DNA
Methylation Start-up kit (Zymo Research). Brieﬂy, 200 ng of genomic DNA in CT
Conversion Reagent buffer was denatured for 8min at 98 C and incubated for
3.5 h at 64 C. After on-column desulfonation, DNA was eluted in 10 ml elution
buffer, and subjected to 40 cycles of PCR ampliﬁcation (95 C for 30 s, 59 C for
30 s, 72 C for 1min) following an initial denaturation step at 95 C for 10min.
Primers in the SHP-1 (PTPN6) promoter (LOU1398, LOU1399, LOU1400 and
LOU1401) were designed using the MethPrimer online software (www.urogene.
org/methprimer/index1.html). Their speciﬁcity for bisulﬁte converted DNA was
veriﬁed by PCR ampliﬁcation of bisulﬁte-treated and -untreated genomic DNA.
PCR products were gel-puriﬁed and cloned into pGEM-T (pGEM-T Easy Vector
System, Promega). Transformants containing recombinant plasmids were selected
by blue/white colony screening and randomly picked up for Sanger sequencing.
Analysis was performed using the QUMA online software63 with the default
conditions (exclusion of sequences with a bisulﬁte conversion rate below 95% or
with an identity to the reference sequence lower than 90%). Statistical analysis was
performed using the GraphPad Prism 6 software.
Oligos:
Region 1, fwd: LOU1398
50-GGTTTGTATAGGGGGTATTTTTTTT-30
Region 1, rev: LOU1399
50-CACCTAAAACTCCACCTAAAACTCA-30
Region 2, fwd: LOU1400
50-AGTTTTAGGTGGAGTTTTAGGTGGT-30
Region 2, rev: LOU1401
50-CAAAAACAAACCCTAAACTAATAATCTC-30 .
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